Xylocaine, Fortacin(lidocaine)
/ Lidocaine, Akten, Duocaine, Embolex, Fortacin, Glydo, Lanabiotic, Laryng-o-jet, Lidocaine, Lidocaine /, Lidoderm, Lignospan, Oraqix, Pliaglis, Rocephin, Synera, Terramycin, Xylocaine, Zingo, Ztlido (lidocaine) is a small molecule pharmaceutical. Lidocaine was first approved as Decadron w/ xylocaine on 1982-01-01. It is used to treat burns, cardiac arrhythmias, esophageal diseases, mouth diseases, and pain amongst others in the USA. It has been approved in Europe to treat physiological sexual dysfunction and premature ejaculation. The pharmaceutical is active against sodium channel protein type 5 subunit alpha. In addition, it is known to target sodium channel protein type 2 subunit alpha, sodium channel protein type 4 subunit alpha, sodium channel protein type 9 subunit alpha, and sodium channel protein type 10 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Akten, Glydo, Laryng-o-jet, Lidocaine, Lidocaine viscous, Lidoderm, Zingo, Ztlido (discontinued: Anestacon, Dentipatch, Laryngotracheal anesthesia, Lidocaine, Lidocaine viscous, Lidopen, Lta, Xylocaine, Xylocaine viscous, Xylocaine w/ glucose)
CombinationsLidocaine epinephrine, Lidocaine prilocaine, Lignospan, Lignospan standard, Oraqix, Xylocaine w/ epinephrine (discontinued: Decadron w/ xylocaine, Duocaine, Embolex, Emla, Iontocaine, Lanabiotic, Lidocaine epinephrine, Lidocaine prilocaine, Lidocaine w/ epinephrine, Lidosite topical system, Octocaine, Pliaglis, Rocephin, Synera, Terramycin, Xylocaine w/ epinephrine, Xylocaine with epinephrine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lidocaine
+
Prilocaine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ORAQIX | Dentsply Pharmaceutical | N-021451 RX | 2003-12-19 | 1 products, RLD, RS |
Show 2 discontinued
Lidocaine
+
Tetracaine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNERA | Galen Pharma | N-021623 DISCN | 2005-06-23 | 1 products, RLD |
| PLIAGLIS | Taro Pharmaceutical | N-021717 DISCN | 2006-06-29 | 1 products, RLD |
Hide discontinued
Ceftriaxone sodium
Ceftriaxone sodium
+
Lidocaine
Lidocaine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZTLIDO | Scilex Pharmaceuticals | N-207962 RX | 2018-02-28 | 1 products, RLD, RS |
| LIDODERM | Teikoku Pharma | N-020612 RX | 1999-03-19 | 1 products, RLD, RS |
Show 5 discontinued
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019830 RX | 1992-04-08 | 1 products |
| LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019830 RX | 1992-04-08 | 1 products |
| LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019830 RX | 1992-04-08 | 1 products |
| LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER | Baxter | N-018461 RX | 1982-01-01 | 1 products |
| LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER | Baxter | N-018461 RX | 1982-01-01 | 1 products |
| LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER | Baxter | N-018461 RX | 1982-02-22 | 1 products |
| LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE | Fresenius Kabi | N-017584 RX | 1982-01-01 | 2 products |
| XYLOCAINE | Fresenius Kabi | N-006488 RX | 1982-01-01 | 4 products, RLD, RS |
| ZINGO | Powder Pharmaceuticals | N-022114 RX | 2007-08-16 | 1 products |
| AKTEN | Thea Pharma | N-022221 RX | 2008-10-07 | 1 products, RLD, RS |
Show 21 discontinued
Epinephrine
+
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XYLOCAINE W/ EPINEPHRINE | Fresenius Kabi | N-006488 RX | 1982-01-01 | 6 products, RLD, RS |
Show 6 discontinued
Dihydroergotamine mesylate
+
Heparin sodium
+
Lidocaine hydrochloride
Dexamethasone sodium phosphate
+
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DECADRON W/ XYLOCAINE | Merck & Co | N-013334 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Bupivacaine hydrochloride
+
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUOCAINE | Amphastar Pharmaceuticals | N-021496 DISCN | 2003-05-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| akten | New Drug Application | 2024-04-19 |
| anestacon | ANDA | 2014-01-10 |
| dentipatch | 2006-07-24 | |
| glydo | ANDA | 2022-01-31 |
| leep redikit | unapproved drug other | 2023-10-26 |
| lidocaine hcl | ANDA | 2013-05-31 |
| lidocaine hydrochloride | New Drug Application | 2022-07-13 |
| lidoderm | New Drug Application | 2022-12-02 |
| lignospan forte | ANDA | 2024-02-05 |
| lignospan standard | ANDA | 2024-02-08 |
Show 26 more
Indications
FDA
EMA
Show 93 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lidocaine Hydrochloride, Zingo, Powder Pharms | |||
| 9370622 | 2035-09-28 | U-1870 | |
| 9358338 | 2035-04-27 | U-1870 | |
| 8540665 | 2029-10-22 | U-1438 | |
| Lidocaine, Ztlido, Scilex Pharms | |||
| 9283174 | 2031-05-10 | DP | |
| 9925264 | 2031-05-10 | DP | U-2267 |
| 9931403 | 2031-05-10 | DP | |
| 10765640 | 2031-05-10 | DP | |
| 10765749 | 2031-05-10 | DP | |
| 11278623 | 2031-05-10 | DP | |
| Lidocaine / Tetracaine, Pliaglis, Taro Pharms | |||
| 10350180 | 2031-01-14 | DP | |
| 10603293 | 2031-01-14 | DP | |
| 10751305 | 2031-01-14 | DP | |
| Lidocaine Hydrochloride, Akten, Thea Pharma | |||
| 8759401 | 2026-07-24 | DP | U-1523 |
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BB: Antiarrhythmics, class ib
— C01BB01: Lidocaine
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AD: Local anesthetics for treatment of hemorrhoids and anal fissures for topical use
— C05AD01: Lidocaine
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AB: Anesthetics for topical use
— D04AB01: Lidocaine
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BB: Amide local anesthetics
— N01BB02: Lidocaine
— N01BB52: Lidocaine, combinations
R: Respiratory system drugs
— R02: Throat preparations
— R02A: Throat preparations
— R02AD: Local anesthetic throat preparations
— R02AD02: Lidocaine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01H: Local anesthetics, ophthalmologic
— S01HA: Local anesthetics
— S01HA07: Lidocaine
— S02: Otologicals
— S02D: Other otologicals in atc
— S02DA: Analgesics and anesthetics
— S02DA01: Lidocaine
Clinical
Clinical Trials
3730 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 12 | 24 | 35 | 71 | 173 | 306 |
| Pain | D010146 | EFO_0003843 | R52 | 15 | 39 | 40 | 75 | 147 | 302 |
| Anesthesia | D000758 | — | — | 6 | 8 | 12 | 27 | 63 | 112 |
| Local anesthesia | D000772 | — | — | 8 | 11 | 14 | 23 | 56 | 108 |
| Syndrome | D013577 | — | — | 3 | 18 | 8 | 13 | 63 | 102 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 8 | 10 | 7 | 16 | 41 | 78 |
| Analgesia | D000698 | — | — | 4 | 3 | 8 | 18 | 45 | 75 |
| Chronic pain | D059350 | HP_0012532 | — | 4 | 7 | 9 | 9 | 49 | 75 |
| Neuralgia | D009437 | EFO_0009430 | — | 6 | 15 | 11 | 12 | 29 | 72 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 7 | 9 | 5 | 11 | 40 | 69 |
Show 537 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | 2 | 14 | 2 | — | 4 | 22 |
| Cystitis | D003556 | EFO_1000025 | N30 | 2 | 14 | 2 | — | 3 | 21 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | 1 | — | 15 | 17 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | 1 | 5 | 1 | — | 10 | 16 |
| Covid-19 | D000086382 | — | — | 4 | 6 | 6 | — | 2 | 15 |
| Temporomandibular joint dysfunction syndrome | D013706 | — | — | 1 | 5 | 1 | — | 8 | 14 |
| Vulvodynia | D056650 | — | N94.81 | 1 | 3 | 2 | — | 7 | 13 |
| Cancer pain | D000072716 | — | G89.3 | — | 4 | 2 | — | 7 | 12 |
| Hyperalgesia | D006930 | — | — | 2 | 6 | 1 | — | 2 | 11 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | 1 | 1 | — | 8 | 10 |
Show 141 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | 1 | — | — | 12 | 13 |
| Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | 8 | 11 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 2 | 1 | — | — | 8 | 11 |
| Vulvar vestibulitis | D054515 | — | N94.810 | 1 | 2 | — | — | 6 | 9 |
| Ulcer | D014456 | MPATH_579 | — | 2 | 3 | — | — | 4 | 9 |
| Recurrence | D012008 | — | — | — | 1 | — | — | 8 | 9 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | 7 | 8 |
| Pruritus | D011537 | HP_0000989 | L29 | 2 | 2 | — | — | 5 | 8 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 1 | — | — | 6 | 7 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | 1 | — | — | 6 | 7 |
Show 129 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroma | D009463 | — | — | 2 | — | — | — | 8 | 10 |
| Nociceptive pain | D059226 | — | — | 1 | — | — | — | 6 | 7 |
| Oropharyngeal neoplasms | D009959 | — | — | 1 | — | — | — | 5 | 6 |
| Tissue adhesions | D000267 | — | — | 6 | — | — | — | — | 6 |
| Morton neuroma | D000070607 | — | G57.6 | 2 | — | — | — | 4 | 6 |
| Squamous cell carcinoma | D002294 | — | — | 2 | — | — | — | 4 | 6 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 3 | 4 |
| Tympanic membrane perforation | D018058 | — | H72 | 1 | — | — | — | 2 | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 2 | 3 |
| Mouth diseases | D009059 | EFO_1001047 | K13 | 2 | — | — | — | 1 | 3 |
Show 47 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 8 | 8 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 8 | 8 |
| Basal cell carcinoma | D002280 | — | — | — | — | — | — | 7 | 7 |
| Piriformis muscle syndrome | D055958 | — | — | — | — | — | — | 7 | 7 |
| Skin aging | D015595 | EFO_0005422 | — | — | — | — | — | 7 | 7 |
| Ultrasonography | D014463 | — | — | — | — | — | — | 6 | 6 |
| Basal cell neoplasms | D018295 | — | — | — | — | — | — | 6 | 6 |
| Esthetics | D004954 | — | — | — | — | — | — | 5 | 5 |
| Video-assisted thoracic surgery | D020775 | — | — | — | — | — | — | 5 | 5 |
| Bronchoscopy | D001999 | — | — | — | — | — | — | 5 | 5 |
Show 402 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lidocaine |
| INN | lidocaine |
| Description | Lidocaine is the monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline. It has a role as a local anaesthetic, an anti-arrhythmia drug, an environmental contaminant, a xenobiotic and a drug allergen. It is a monocarboxylic acid amide, a tertiary amino compound and a member of benzenes. It is functionally related to a glycinamide. |
| Classification | Small molecule |
| Drug class | local anesthetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CC(=O)Nc1c(C)cccc1C |
Identifiers
| PDB | — |
| CAS-ID | 137-58-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL79 |
| ChEBI ID | 6456 |
| PubChem CID | 3676 |
| DrugBank | DB00281 |
| UNII ID | 98PI200987 (ChemIDplus, GSRS) |
Target
Agency Approved
SCN5A
SCN5A
Organism
Homo sapiens
Gene name
SCN5A
Gene synonyms
NCBI Gene ID
Protein name
sodium channel protein type 5 subunit alpha
Protein synonyms
cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit, hH1, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type V subunit alpha, sodium channel, voltage-gated, type V, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.5
Uniprot ID
Mouse ortholog
Scn5a (20271)
sodium channel protein type 5 subunit alpha (Q9JJV9)
Alternate
TRPV6
TRPV6
SCN2A
SCN2A
SCN10A
SCN10A
Organism
Homo sapiens
Gene name
TRPV6
Gene synonyms
ECAC2
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily V member 6
Protein synonyms
Alu-binding protein with zinc finger domain, Calcium transport protein 1, calcium transporter-like protein, CaT-L, CaT-like, CaT1, ECaC2, epithelial apical membrane calcium transporter/channel CaT1, Epithelial calcium channel 2
Uniprot ID
Mouse ortholog
Trpv6 (64177)
transient receptor potential cation channel subfamily V member 6 (Q91WD2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lidocaine – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lidocaine – Amphastar Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Rocephin – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Lidocaine
+
Diphenhydramine
+
Nystatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lidocaine
+
Hydrocortisone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lidocaine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lidocaine
+
Prilocaine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 91,460 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37,651 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use